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Thalassaemia is a blood disorder in which an 
abnormal form of haemoglobin is made due to genetic 
aberration. Although no national database exists to 
calculate the exact number of thalassaemics, but it is 
estimated that there are 9.8 million carriers of the disease 
in Pakistan [1]. Consanguineous marriage is the leading 
cause for this high prevalence rate due to which the 
thalassaemia gene is trapped within the affected families. 
These patients are dependent on regular blood 
transfusions to sustain life in addition to expensive 
chelation therapy and other medical management. As a 
result, thalassaemia is a major healthcare challenge and 
places great psychological and financial trauma on the 
affected families and is a huge burden on the national 
healthcare delivery system [2].  
As the thalassaemia major patients are 
dependent on regular transfusions to sustain life [1], a 
common adverse effect of chronic transfusions in these 
patients is Febrile Non-Haemolytic Transfusion Reaction 
(FNHTR) with an occurrence rate of about 0.5-6.8% [3]. 
The FNHTRs occur due to immune reaction of the 
recipient against donor leucocytes [4]. Leucodepletion is a 
process of removing leucocytes from the donated blood 
either during blood collection, processing or at the 
bedside. The average amount of leucocytes present in 
donated human blood is estimated to be 109 per unit. 
According to the guidelines, the total amount of 
leucocytes present in a blood unit should be less than 5 x 
106 per unit after preparation  [5]. 
A pilot study was carried out in three major 
thalassaemia centres of Islamabad and Rawalpindi 
(Pakistan Institute of Medical Sciences Thalassaemia 
Centre; Pakistan Bait ul Mal Thalassaemia Centre; Jamila 
Sultana Thalassaemia Centre) on 120 thalassaemic 
patients with history of mild to moderate transfusion 
reactions. The study was conducted from January – April 
2018, and the ethical consent was given by the ethical 
review board of Pakistan Institute of Medical Sciences, 
Islamabad. Written consent was taken from patients (or 
their parents) before the start of transfusions and the 
results were analyzed using Microsoft Excel 2013. 
LeucoliteTM filters (by GLT Medical Co., Ltd.) were used 
during transfusion to the selected 120 patients. In the 
past, these patients were routinely given pre-medication 
[Solu-Cortef (100 Mg) and Avil Injections] to avoid 
transfusion reactions but with the leucofilter use, no pre-
medications was given to observe the effectiveness of the 
leucofilters. The age of transfused red cell concentrates 
ranged from 5-27 days. No transfusion reaction of any 
kind was observed in any of the patients using the 
leuofilters. 
 
A study conducted by Waheed et al., [6] on 
thalassaemia major cases, reported an incidence of 
26.3% transfusion associated reactions in a total of 2,193 
red cell transfusions, with FNHTR being the most 
common reaction. In the present study, reaction rate 
declined to 0%, when bedside filter was used and no 
FNTHRs were documented on cases which had earlier 
reported high incidence of FNTHRs. On the other hand, 
use of non leuco-reduced blood resulted in the 
occurrence of febrile non-haemolytic transfusion reactions 
with a reaction rate of 100%. This shows that a 
remarkable reduction occurs in FNTHRs when bedside 
filter leuco-reduced blood is transfused as compared to 
non-leucoreduced blood. Hence, leucoreduction of blood 
components in thalassaemic patients can be helpful in 
preventing transfusion reactions. Anecdotal evidence 
claims no effect on the rate of FNHTRs but that is 
invariably in those centres where the sub-standard filters 
are being used. The leucofilters sale thus needs to be 
regulated by the government. This is an on-going study, 
leucofilters will be used consistently on thalassaemics and 
other chronic recipients to assess the effectiveness of 
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leucodepletion and co-relate it with financial impact 
including prolonging duration of interval of transfusion. 
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